Loading...
XNAS
MDGL
Market cap6.46bUSD
May 16, Last price  
290.96USD
1D
-0.29%
1Q
-13.71%
Jan 2017
1,852.75%
IPO
2,915.13%
Name

Madrigal Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
35.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.68%
Rev. gr., 5y
%
Revenues
180m
00743,0002,615,000144,245,00014,803,0007,584,000147,00000000000000180,133,000
Net income
-466m
L+24.69%
-68,863,000-57,270,000-63,495,000-92,618,00079,088,000-37,467,000-47,380,000-62,790,000-90,192,000-86,161,000-68,671,000-26,388,000-31,154,000-32,811,000-72,812,000-197,444,000-241,078,000-299,314,000-373,630,000-465,892,000
CFO
-456m
L+40.51%
-61,882,000-52,985,00027,222,000-37,939,000-26,810,000-38,199,000-47,300,000-54,135,000-77,411,000-78,925,000-71,444,000-17,607,620-22,317,000-25,507,000-41,624,000-157,561,000-183,917,000-224,857,000-324,230,000-455,572,000
Earnings
Aug 05, 2025

Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
URL
https://www.madrigalpharma.com/
IPO date
Feb 06, 2007
Employees
92
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
180,133
 
Cost of revenue
242,951
381,023
294,038
Unusual Expense (Income)
NOPBT
(62,818)
(381,023)
(294,038)
NOPBT Margin
Operating Taxes
3,964
Tax Rate
NOPAT
(62,818)
(381,023)
(298,002)
Net income
(465,892)
24.69%
(373,630)
24.83%
(299,314)
24.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
397,487
260,187
255,382
BB yield
-6.06%
-6.02%
-5.13%
Debt
Debt current
1,966
1,054
602
Long-term debt
2,001
118,379
49,891
Deferred revenue
Other long-term liabilities
117,569
Net debt
(922,284)
(514,698)
(308,281)
Cash flow
Cash from operating activities
(455,572)
(324,230)
(224,857)
CAPEX
(1,462)
(1,479)
(217)
Cash from investing activities
(274,386)
(502,520)
206,686
Cash from financing activities
735,062
595,116
313,451
FCF
(64,143)
(383,086)
(297,557)
Balance
Cash
926,251
634,131
358,774
Long term investments
Excess cash
917,244
634,131
358,774
Stockholders' equity
(1,801,712)
(1,335,820)
(962,690)
Invested Capital
2,676,648
1,858,873
1,209,970
ROIC
ROCE
EV
Common stock shares outstanding
21,273
18,688
17,137
Price
308.57
33.36%
231.38
-20.28%
290.25
242.52%
Market cap
6,564,198
51.81%
4,323,977
-13.07%
4,974,073
254.99%
EV
5,641,914
3,809,279
4,665,792
EBITDA
(62,122)
(380,496)
(293,571)
EV/EBITDA
Interest
14,671
12,712
3,964
Interest/NOPBT